Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $21.9 million.

  • United Therapeutics' Depreciation & Amortization (CF) rose 1465.97% to $21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.5 million, marking a year-over-year increase of 2406.02%. This contributed to the annual value of $72.5 million for FY2024, which is 3627.82% up from last year.
  • United Therapeutics' Depreciation & Amortization (CF) amounted to $21.9 million in Q3 2025, which was up 1465.97% from $21.1 million recorded in Q2 2025.
  • In the past 5 years, United Therapeutics' Depreciation & Amortization (CF) registered a high of $21.9 million during Q3 2025, and its lowest value of $12.4 million during Q2 2021.
  • Its 5-year average for Depreciation & Amortization (CF) is $15.2 million, with a median of $13.3 million in 2023.
  • Per our database at Business Quant, United Therapeutics' Depreciation & Amortization (CF) crashed by 381.68% in 2021 and then soared by 4496.12% in 2024.
  • Quarter analysis of 5 years shows United Therapeutics' Depreciation & Amortization (CF) stood at $12.6 million in 2021, then rose by 4.76% to $13.2 million in 2022, then increased by 3.79% to $13.7 million in 2023, then skyrocketed by 43.8% to $19.7 million in 2024, then grew by 11.17% to $21.9 million in 2025.
  • Its last three reported values are $21.9 million in Q3 2025, $21.1 million for Q2 2025, and $19.8 million during Q1 2025.